Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of metformin versus placebo, including three insulin-analogue regimens with variating postprandial glucose regulation, on CIMT in T2DM patients - A randomized, multicenter trial.

Trial Profile

The effect of metformin versus placebo, including three insulin-analogue regimens with variating postprandial glucose regulation, on CIMT in T2DM patients - A randomized, multicenter trial.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart (Primary) ; Insulin detemir (Primary) ; Metformin (Primary)
  • Indications Diabetic angiopathies; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CIMT
  • Most Recent Events

    • 01 Jan 2022 Results of a post hoc analysis assessing the effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes published in the Free Radical Biology and Medicine
    • 01 Sep 2021 Results of exploratory sub-study of the Copenhagen Insulin and Metformin Therapy trial (n=407) assessing long-term effects of metformin compared with placebo on whole body bone and body composition measures in patients with type 2 diabetes mellitus, published in the Osteoporosis International.
    • 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top